Healthcare / Medical DevicesCopenhagen
$357.40
-17.60 (-4.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $113.3M · quality 80.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.2B
P/E
35.2x
↑EV/EBITDA
22.5x
↑ROE
27.7%
↑Gross Margin
93.9%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.0%
FCF CAGR
+5.7%
FCF margin
28.8%
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $495.6M · net income $186.4M · FCF $142.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $495.6M | $495.6M | $407.9M | $444.4M | $428.4M |
| Net Income | $186.4M | $186.4M | $136.3M | $178.7M | $159.5M |
| EBITDA | $262.1M | $262.1M | $194.0M | $251.8M | $224.8M |
| EPS | 10.71 | 10.71 | 7.83 | 10.27 | 9.16 |
| Gross Margin | 93.9% | 93.9% | 90.1% | 92.6% | 89.7% |
| Operating Margin | 47.7% | 47.7% | 41.4% | 51.9% | 47.3% |
| Net Margin | 37.6% | 37.6% | 33.4% | 40.2% | 37.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 3.93 | 3.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $142.7M | $142.7M | $85.5M | $113.3M | $120.9M |
| Returns | |||||
| ROE | 27.7% | 27.7% | 24.1% | 33.5% | 44.6% |
| Valuation | |||||
| P/E | 35.18 | 35.18 | 46.05 | 42.51 | 87.17 |
| EV/EBITDA | 22.45 | 22.45 | 30.85 | 28.94 | 60.91 |
| P/B | 9.24 | 9.24 | 11.10 | 14.25 | 38.90 |
| Growth & Yield | |||||
| Revenue Growth | 21.5% | 21.5% | -8.2% | 3.7% | — |
| EPS Growth | 36.8% | 36.8% | -23.8% | 12.1% | — |
| Dividend Yield | 1.9% | 1.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
43.6%
EPS terminal req.
$31.71
Spread vs growth
-6.8%
5Y implied EPS CAGR
29.1%
EPS terminal req.
$38.37
Spread vs growth
7.7%
10Y implied EPS CAGR
19.2%
EPS terminal req.
$61.80
Spread vs growth
17.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.4%
Start / end P/E
65.5x → 33.4x
EPS bridge
7.83 → 10.71
Residual
-18.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.